Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Haleon PLC ( (GB:HLN) ) is now available.
Haleon plc has granted conditional share awards to Chief Executive Officer Brian McNamara and Chief Financial Officer Dawn Allen under its Performance Share Plan and Deferred Annual Bonus Plan. The awards, totaling 1,813,680 shares for McNamara and 808,297 shares for Allen at nil cost, reflect the company’s executive pay framework and are subject to performance conditions running through year-end 2028, as well as malus and clawback provisions, underscoring Haleon’s alignment of leadership incentives with long-term performance and shareholder interests.
The transactions, executed outside a trading venue on 12 March 2026, form part of Haleon’s regular remuneration policy for persons discharging managerial responsibilities. By tying a significant portion of top executives’ compensation to equity-based awards with defined performance targets, the company reinforces its focus on sustained value creation and governance discipline within the competitive consumer health sector.
The most recent analyst rating on (GB:HLN) stock is a Buy with a £450.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Neutral.
The score is driven primarily by solid financial performance (consistent free cash flow and improving profitability) and a cautiously positive earnings outlook supported by margin gains and cost savings. This is tempered by weaker near-term technical momentum and only moderate valuation support.
To see Spark’s full report on GB:HLN stock, click here.
More about Haleon PLC
Haleon plc, listed in London and New York, is a consumer healthcare company focused on improving everyday health. Its portfolio spans oral health, vitamins, minerals and supplements, pain relief, respiratory and digestive health, and therapeutic skin health, led by global brands such as Advil, Panadol, Sensodyne, Voltaren, Centrum and Theraflu, used by over a billion consumers and recommended by health professionals worldwide.
Average Trading Volume: 18,282,319
Technical Sentiment Signal: Sell
Current Market Cap: £33.23B
See more insights into HLN stock on TipRanks’ Stock Analysis page.